Could Intercept Pharmaceutical be the Pump and Dump of the month or even the year

Intercept Pharmaceutical on the Pump and Dump watch

From pure technicals the stock did break out but it hit resistance heavily at $128.75 and has been down trending ever since 12:50 with the lowest price coming $92.45 3 mins after close on 18,570 shares 28.19% drop. Some dumped read on to find out why.

If you look back last month I gave a similar warning on Synaptics $SYNA you can see how that played out, Intercept Pharmaceutical $ICPT is now playing that same game.

With the earnings miss of $0.46 a share it proves that the company is not profitable even though they have $558.7 million in cash. Due to 2 reasons that money came from TWO (2) public follow ons in 2015 and they estimate a need of $400 million just for the current trials alone. Any new trials will require more funding with such a small float the dilution could be as much as 20% in share float.

Intercept posts SEC 13G listed 6.4% ownership = 1,567,537 on FEB10th NO PRICE listed for avg share means this is worthless information but you can bet the acquisition was completed in the price $91.44-$96.01 or much lower.  http://www.sec.gov/Archives/edgar/data/1270073/000142284916000618/edgicpt.txt

Less than 10% can sell at their hearts content into any pop which makes this an easy game, file 13G with no share per price avg, bump price, halt it saying looking for buyer, sell into pop, dump after hours if needed. Technical traders would have bought the break out and would not see the after hours drop on any intraday scans.

Based on this intercept is a better short than long because the fundamentals have not changed this still is not going to make any money till the FDA approves and that is not a sure thing.

Results weren`t great in trial but they were positive in using obeticholic acid as a treatment for primary biliary cirrhosis, or PBC, an autoimmune disease that causes bile acids to build up and destroy the liver.

Originally, obeticholic acid, also known as OCA, was slated to be approved (or given a complete response letter detailing what would need to be corrected for approval) in February. However, additional data requests from the Food and Drug Administration wound up pushing the PDUFA date back three months, to May 29, 2016. The FDA also set up a panel review for April 7, 2016.

If this was a sure thing then why do we have selling from insiders and the dump at 4:03 of 18,570 shares with a final price of $92.45.

Insiders selling none are buying since 2014

Insider Trading: Sales

Insider	Price	Amount	Relationship	Remaining Holdings	Date	Form 4
Mcminn	$103.56	128	Officer	7,621	2016-02-01	Filing
Bright	$129.99	104	Officer	11,700	2016-01-13	Filing
Bright	$124.78	624	Officer	11,804	2016-01-12	Filing
Mcminn	$145.90	469	Officer	7,749	2016-01-04	Filing
Duncan	$145.90	428	Officer	24,892	2016-01-04	Filing
Duncan	$145.90	40	Officer	25,320	2016-01-04	Filing
Shapiro	$145.90	496	Officer	40,911	2016-01-04	Filing
Shapiro	$145.90	37	Officer	41,407	2016-01-04	Filing
Pruzanski	$145.90	125	Officer, Director	529,556	2016-01-04	Filing
Pruzanski	$145.90	2,001	Officer, Director	529,681	2016-01-04	Filing
Shapiro	$157.45	1,000	Officer	28,395	2015-12-15	Filing
Shapiro	$157.38	2,500	Officer	29,395	2015-12-15	Filing
Bright	$182.96	1,150	Officer	12,428	2015-11-25	Filing
Williams	$167.00	973	Director	962	2015-11-20	Filing
Shapiro	$179.49	1,500	Officer	28,395	2015-11-16	Filing
Shapiro	$178.00	2,764	Officer	29,895	2015-11-16	Filing
Veitinger	$198.25	1,000	Director	2,166	2015-11-10	Filing
Shapiro	$204.15	3,500	Officer	29,159	2015-11-10	Filing
Mcminn	$160.24	125	Officer	8,218	2015-11-02	Filing
Williams	$182.22	974	Director	962	2015-10-20	Filing

Insider Trading: Purchases

Insider	Price	Amount	Relationship	Remaning Holdings	Date	Form 4
Benatti	$139.86	800	Director	1,292	2014-12-15	Filing
Akkaraju	$163.27	500	Director	7,642	2014-11-12	Filing
Akkaraju	$173.67	1,000	Director	7,142	2014-11-12	Filing
Akkaraju	$158.18	500	Director	6,142	2014-11-12	Filing
Orbimed	$15.00	333,334	Large Shareholder	2,150,634	2012-10-16	Filing
Akkaraju	$15.00	700,000	Director	700,000	2012-10-16	Filing
Silverstein	$15.00	333,334	Large Shareholder, Director	2,150,634	2012-10-16	Filing

http://www.insidermonkey.com/insider-trading/company/intercept+pharmaceuticals+inc/1270073/purchases/

Lastly if someone did want to buy this company why would they pay a premium, buy before the FDA approval and why would the company be looking now to sell so close to the "approval"? Smells fishy $SYNA fishy to me

Based on this I am calling this a SHORT not a squeeze.